FIGURE 3.

Molecular landscape of ROS1‐fusion‐positive CRCs. (A) Frequency of tumors classified as MSI‐H, genome‐wide loss of heterozygosity (gLOH) high and TMB‐high by FoundationOne test in the ROS1 rearranged vs nonrearranged cohort. (B) Most common concomitant mutations (SNVs) in ROS1 rearranged vs nonrearranged CRCs; **P = .0029; (C) Difference in relative mutational frequency of concomitant genomic alterations, enriched in the ROS1 rearranged vs nonrearranged cohort; p values (Fisher's exact test) are shown in the Y axis. CRC, metastatic colorectal cancer; RE+, rearranged; RE−, nonrearranged; SNV, single nucleotide variants